natgillin/translations-raw huggingface dataset:
Resistens over for efavirenz
Resistance to efavirenz
Resistens over for emtricitabin/lamivudin
Resistance to emtricitabine/lamivudine
resistens over for hiv-
resistance to the HIV regimen.
Resistens over for imatinib inkluderede manglende fuldstændig hæmatologisk respons (ved måneder), cytogenetisk respons (ved 6 måneder) eller større cytogenetisk respons (ved 12 måneder) eller sygdomsprogression efter en tidligere cytogenetisk eller hæmatologisk respons.
Resistance to imatinib included failure to achieve a complete haematological response (by 3 months), cytogenetic response (by 6 months) or major cytogenetic response (by 12 months) or progression of disease after a previous cytogenetic or haematological response.
Resistens over for makrolider skyldes almindeligvis tre mekanismer: (1) Ændringen af det ribosomale angrebspunkt (methylering), som ofte kaldes MLSB-resistens, da det påvirker makrolider, lincosaminer og gruppe B streptograminer. (2) Anvendelse af aktive effluksmekanismer. (3) Produktion af inaktiverende enzymer.
Resistance to macrolides generally results from three mechanisms: (1) the alteration of the ribosomal target site (methylation), often referred to as MLSB resistance as it affects macrolides, lincosamides and group B streptogramins, (2) the utilisation of active efflux mechanism; (3) the production of inactivating enzymes.
Resistens over for makrolider skyldes almindeligvis tre mekanismer: (1) Ændringen af det ribosomale angrebspunkt (methylering), som ofte kaldes MLSB-resistens, da det påvirker makrolider, lincosaminer og gruppe B streptograminer. (2) Anvendelse af aktive effluksmekanismer. (3) Produktion af inaktiverende enzymer.
Resistance to macrolides generally results from three mechanisms: (1) the alteration of the ribosomal target site (methylation), often referred to as MLSB resistance as it affects macrolides, lincosamides and group B streptogramins; (2) the utilisation of active efflux mechanism; (3) the production of inactivating enzymes.
Resistens over for rilpivirin
Resistance to rilpivirine
Resistens over for rilpivirin1 Krydsresistens2 over for etravirin efavirenz nevirapin
Resistance to rilpivirine2 Cross resistance3 to etravirine efavirenz nevirapine
Resistens over for simeprevir blev desuden undersøgt i analyser af HCV- genotype 1a- og 1b-replikoner med anvendelse af målrettede mutanter og kimære replikoner, der bærer NS-sekvenser fra kliniske isolater.
Additionally, resistance to simeprevir was evaluated in HCV genotype 1a and 1b replicon assays using site-directed mutants and chimeric replicons carrying NS3 sequences derived from clinical isolates.
Resistens over for svampemidler af azoltypen skyldes oftest en ændring i cyp51A-genet, der koder for målenzymet 14-alfa-sterol demethylase.
Resistance to azole antifungals is most commonly exhibited by modification of the cyp51A gene which encodes for the target enzyme 14-alpha-sterol demethylase.
Resistens overfor lopinavir, defineret som tilstedeværelse af enhver primær eller mutation idet aktive site i protease (se ovenfor), blev observeret hos 0/51 (0%) patienter.
Resistance to lopinavir, defined as the presence of any primary or active site mutations in protease (see above), was observed in 0/51 (0%) patients.
Resistens# over for emtricitabin/lamivudin
Resistance# to emtricitabine/lamivudine
Resistens: Der er ikke blevet identificeret nogle HBV-mutationer med relation til tenofovirdisoproxilfumarat-resistens (se Klinisk virkning og sikkerhed).
Resistance: No HBV mutations associated with tenofovir disoproxil fumarate resistance have been identified (see Clinical efficacy and safety).
Resistens: Viralt udbrud fra nelfinavir kan forekomme via virale proteasemutationer i aminosyrepositioner 30, 88 og 90.
Resistance: Viral escape from nelfinavir can occur via viral protease mutations at amino acid positions 30, 88 and 90.
Resistensniveauerne over for atazanavir strakte sig fra 3,5 til 29 gange uden tegn på fænotypekrydsresistens over for andre PI’er (proteasehæmmere).
Resistance levels to atazanavir ranged from 3.5- to 29-fold without evidence of phenotypic cross resistance to other PIs.
Resistensniveauerne over for atazanavir strakte sig fra 3,5 til 29 gange uden tegn på fænotypekrydsresistens over for andre PI’er.
Resistance levels to atazanavir ranged from 3.5- to 29-fold without evidence of phenotypic cross resistance to other PIs.
resistensprotein/ABCG2) og P-gp
acute P-gp inhibition by Kaletra
Resistensudvikling optræder primært på grund af ændringer ved bindingsstedet forbundet med mutationer af DNA generne i ribosomet.
Resistance development primarily occurs because of changes at the binding site associated with mutations of the ribosomal DNA genes.
Resistent over for tidligere TKI-behandling a*, n (%)
Resistant to Prior TKI Therapy a *, n (%)
Resistent over for tidligere TKI-behandlinga*, n (%)
Resistant to Prior TKI Therapy a *, n (%)
Reskonstitueret opløsning af Zometa må ikke blandes med calcium eller anden divalent kationholdig infusionsopløsning såsom Ringer-lactatopløsning, og bør indgives som en enkelt intravenøs opløsning i en separat infusionsslange.
Zometa reconstituted solution must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Reslizumab 3 mg/kg
Reslizumab 3 mg/kg (n=245)
Reslizumab binder specifikt til IL-5 og interfererer med IL-5-bindingen til receptoren på celleoverfladen.
Reslizumab binds specifically to IL-5 and interferes with IL-5 binding to its cell-surface receptor.
Reslizumab binder til humant IL-5 med pikomolær affinitet og blokerer den biologiske funktion, hvorfor overlevelsen og aktiviteten af eosinofile celler reduceres.
Reslizumab binds human IL-5 with picomolar affinity blocking its biological function; consequently survival and activity of eosinophils are reduced.
Reslizumab er et humaniseret monoklonalt antistof, som fremstilles i myelomceller (NS0) fra mus ved rekombinant dna-teknologi.
Reslizumab is a humanised monoclonal antibody produced in mouse myeloma cells (NS0) by recombinant DNA technology.
Reslizumab fremviste signifikant reduktion i antal astmaeksacerbationer i forhold til placebo hos den refraktære population (59 %) og hos den ikke-refraktære population (49 %).
Reslizumab produced significant reductions in asthma exacerbations relative to placebo in the refractory population (59%) and non-refractory population (49%).
Reslizumabs farmakokinetik var ikke signifikant forskellig mellem mænd og kvinder.
The pharmacokinetics of reslizumab was not significantly different between males and females.
Resocortol butyrat 1 mg/g
Resocortol butyrate 1 mg/g
Resocortol butyrat 1 mg/g
Resocortol butyrate 1mg/g
Resocortol butyrat: 1 mg/g
Resocortol butyrate: 1mg/g
Resolor 1 mg filmovertrukne tabletter er hvide til råhvide, runde tabletter mærket med ’PRU 1’ på den ene side.
Resolor 1 mg film-coated tablets are white to off-white round shaped tablets marked “PRU 1” on one side.
Resolor 2 mg filmovertrukne tabletter er lyserøde, runde tabletter mærket med ’PRU 2’ på den ene side.
Resolor 2 mg film-coated tablets are pink round shaped tablets marked “PRU 2” on one side.
Resolor anbefales ikke til gravide.
Resolor is not recommended during pregnancy.
Resolor kan tages sammen med eller uden mad og drikke når som helst i løbet af dagen.
Resolor can be taken with or without food and drinks, at any time of the day.
Resolors sikkerhed og virkning hos patienter med svær og klinisk ustabil sygdom (f.eks. hjerte-kar- eller lungesygdom, neurologiske eller psykiatriske lidelser, kræft eller aids og endokrine sygdomme) er ikke blevet klarlagt i kontrollerede kliniske studier.
The safety and efficacy of Resolor for use in patients with severe and clinically unstable concomitant disease (e.g. cardiovascular or lung disease, neurological or psychiatric disorders, cancer or AIDS and other endocrine disorders) have not been established in controlled clinical trials.
Resolors virkning blev påvist i tre randomiserede, dobbeltblindede, placebokontrollerede multicenterstudier af 12 ugers varighed hos studiepersoner med kronisk obstipation (n = 1.279 på Resolor; 1.124 kvinder og 155 mænd).
The efficacy of Resolor was established in three multicentre, randomised, double-blind, 12-week placebo-controlled studies in subjects with chronic constipation (n=1,279 onResolor, 1,124 females, 155 males).
Resolors virkning og sikkerhed hos pædiatriske patienter (i alderen 6 måneder til 18 år) med funktionel obstipation blev undersøgt i et 8 ugers, dobbeltblindt, placebokontrolleret studie (N = 213) efterfulgt af et 16-ugers åbent komparatorkontrolleret (polyethylenglycol 4000) studie på op til 24 uger (N = 197).
The efficacy and safety of Resolor in paediatric patients (aged 6 months to 18 years) with functional constipation, were evaluated in an 8-week double-blind, placebo-controlled trial (N = 213), followed by a 16 week open-label comparator-controlled (Polyethylene glycol 4000) study of up to 24 weeks (N = 197).
Resolution forekom hos 116 patienter (92,8%) med en mediantid til resolution på 5,0 uger (0,1-53,1).
Resolution occurred in 116 patients (92.8%) with a median time to resolution of 5.0 weeks (range: 0.1-53.1).
Resolution forekom hos 17 patienter (89,5%) med en mediantid til resolution på 1,9 uger (0,4-42,6+).
Resolution occurred in 17 patients (89.5%) with a median time to resolution of 1.9 weeks (range: 0.4- 42.6+).
Resolution forekom hos 192 patienter (67,6%) med en mediantid til resolution på 10,4 uger (0,1-74,0+).
Resolution occurred in 192 patients (67.6%) with a median time to resolution of 10.4 weeks (range: 0.1-74.0+).
Resolution forekom hos 2 patienter (67%) med en mediantid til resolution på
Resolution occurred in 2 patients (67%) with a median time to resolution of
Resolution forekom hos 207 patienter (89%) med en mediantid til resolution på 2,1 uger (0,1-88,3+).
Resolution occurred in 207 patients (89%) with a median time to resolution of 2.1 weeks (range: 0.1-88.3+).
Resolution forekom hos 295 patienter (62%) med en mediantid til resolution på 18,1 uger (0,1-113,7+).
Resolution occurred in 295 patients (62%) with a median time to resolution of 18.1 weeks (0.1- 113.7+).
Resolution forekom hos 47 patienter (84%) med en mediantid til resolution på 5,3 uger (0,6-53,1+); + betegner en censureret observation.
Resolution occurred in 47 patients (84%) with a median time to resolution of 5.3 weeks (range: 0.6-53.1+); + denotes a censored observation.
Resolution forekom hos 5 patienter (71%), herunder den ene patient med et grad 3 tilfælde, med en mediantid til resolution på 5,9 uger (0,7-37,6+); + betegner en censureret observation.
Resolution occurred in 5 patients (71%), including the Grade 3 case, with a median time to resolution of 5.9 weeks (range: 0.7- 37.6+); + denotes a censored observation.
Resolution forekom hos 59 patienter (45,0%).
Resolution occurred in 59 patients (45.0%).
Resolution forekom hos 6 patienter (50%) med en mediantid til resolution på 20,6 uger (0,4-47,6+); + betegner en censureret observation.
Resolution occurred in 6 patients (50%) with a median time to resolution of 20.6 weeks (0.4-47.6+); + denotes a censored observation.
Resolution forekom hos 74 patienter (45%) med en mediantid til resolution på 66,6 uger (0,4-96,1+).
Resolution occurred in 74 patients (45%) with a median time to resolution of 66.6 weeks (0.4-96.1+).
Resolution forekom hos 95 patienter (79%) med en mediantid til resolution på 5,1 uger (0,1-82,6+).
Resolution occurred in 95 patients (79%) with a median time to resolution of 5.1 weeks (range: 0.1-82.6+).
Resoriblet, sublingual
Sublingual tablet
Resoribletten bør ikke tages ud af blisterpakningen, før den skal indtages.
The tablet should not be removed from the blister until ready to take it.
Resoribletten vil blive opløst af spyt i løbet af få sekunder.
The tablet will dissolve in saliva within seconds.
Resoribletter, sublinguale
Sublingual tablet
RESPIPORC FLU3 indeholder små mængder af en modificeret og herefter dræbt form at svineinfluenza, som forårsager læsioner og sygdom.
RESPIPORC FLU3 contains small amounts of a modified and then killed form of the pig’s influenza virus that causes lesions and illness.
RESPIPORC FLU3 injektionsvæske, suspension, til svin
RESPIPORC FLU3 suspension for injection for pigs
RESPIPORC FLU3 injektionsvæske, suspension, til svin.
RESPIPORC FLU3 suspension for injection for pigs
Respiration sstop
Respiratory arrest
Respirations-
Anhidrosis
Respirations-
mediastinal
respirations-
respiratory
Respirations-
Skin and
Respirations- depression Søvnapnø- syndrom
Respiratory depression Sleep apnoea syndrome
Respirations- forstyrrelser
Respiratory disorder
respirations- svigt4
hypoxia
respirations- svigt4
pruritis, rash,
Respirationsbesvær, dyspnø
Respiratory distress, Dyspnoea
Respirationsbesvær, orofaryngeale smerter, hoste, dysfoni
respiratory disorder, oropharyngeal pain, cough, dysphonia
respirationsdepression (se
(saquinavir/ritonavir)
Respirationsdepression efter overdosering kan vare længere end effekten af opioid–antagonisten (f.eks. er halveringstiden af naloxon mellem 30 og 81 minutter), og gentagen indgivelse kan være nødvendig.
The duration of respiratory depression following overdose may be longer than the effects of the opioid antagonist’s action (e.g., the half-life of naloxone ranges from 30 to 81 minutes) and repeated administration may be necessary.
respirationsdepression og/eller
depression and/or prolonged
respirationsdepression og/eller
monitoring for respiratory
Respirationsdepression som følge af depression af centralnervesystemet er det primære symptom, som kræver indgriben i tilfælde af overdosering, da det kan forårsag åndedrætsstop og død.
Respiratory depression as a result of central nervous system depression is the primary symptom requiring intervention in the case of overdose because it may lead to respiratory arrest and death.
Respirationsdepression, epistaxis, nasale sår rinoré
Respiratory depression, epistaxis, nasal ulcer, rhinorrhea
Respirationsdepression, epistaxis, nasale sår, rinoré
Respiratory depression, epistaxis, nasal ulcer, rhinorrhea
Respirationsdpression kan føre til respiratorisk acidose og respirationsstop (ved sevoflurankoncentrationer på 2,0 MAC og derover) hos spontant respirerende hunde.
Respiratory depression may lead to respiratory acidosis and respiratory arrest (at sevoflurane concentrations of 2.0 MAC and above) in spontaneously breathing dogs.
Respirationsrelaterede hændelser
Respiratory events
Respirationss top
Respiratory arrest
Respirationsstatus, blodtryk, væskebalance og vægt bør kontrolleres løbende under og umiddel- bart efter de fem dages aktiv behandling med clofarabin.
Respiratory status, blood pressure, fluid balance and weight throughout and immediately after the 5 day clofarabine administration period.
Respirationssvig ta
Respiratory failurea
respirationssvigt, akut respiratorisk distress syndromb, lungeinfiltrat, lungeødem, pneumonitis, allergisk rhinitis
respiratory failure, acute respiratory distress syndromeb, lung infiltration, pulmonary oedema, pneumonitis, allergic rhinitis
Respirationssvigt, akut respiratory distress syndrome, apnø, pneumothorax, atelektase, pulmonal hypertension, hæmoptysis, hyperventilation, ortopnø, pneumonitis, respiratorisk baseosis, takypnø, lungefibrose, bronkiesygdom*, hypokapni*, interstitiel lungesygdom, lungeinfiltration, sammensnøring af halsen, tør i halsen, øget sekret i de øvre luftveje, halsirritation, øvre luftvej- hoste-syndrom
Respiratory failure, Acute respiratory distress syndrome, Apnoea, Pneumothorax, Atelectasis, Pulmonary hypertension, Haemoptysis, Hyperventilation, Orthopnoea, Pneumonitis, Respiratory alkalosis, Tachypnoea, Pulmonary fibrosis, Bronchial disorder*, Hypocapnia*, Interstitial lung disease, Lung infiltration, Throat tightness, Dry throat, Increased upper airway secretion, Throat irritation, Upper-airway cough syndrome
Respirationssvigta
Pulmonary oedemaa
Respiratorassocieret pneumoni
Ventilator-associated pneumonia
Respiratorisk
Respiratory
Respiratorisk forstyrrelse
Respiratory disorder
Respiratorisk insufficiens
Respiratory insufficiency
Respiratorisk insufficiens
Uncommon (1/1000, <1/100)
Respiratoriske lægemidler
Respiratory Drugs
Respiratoriske sygdomme
Respiratory disorders:
Respiratoriske sygdomme (tilgrundliggende lungesygdomme)
Respiratory Diseases (Underlying Lung Disease)
Respiratoriske, thorax- og mediastina-lidelser
Respiratory, thoracic and mediastinal disorders
Respirérbar dosis < 5 µm [mg±SD]
Fine Particle Mass < 5 µm [mg±SD]
Respon- denter
Responders
RESPOND-2 (P05101) var et randomiseret, dobbeltblindet studie med parallelle grupper, der sammenlignede to behandlingsregimer med Victrelis 800 mg oralt tre gange dagligt i kombination med PR [peginterferon alfa-2b 1,5 µg/kg/uge subkutant og vægtbaseret ribavirin (600  1.400 mg to gange dagligt) oralt fordelt på to daglige doser] sammenlignet med PR alene hos voksne forsøgspersoner med kronisk hepatitis C hcv genotype 1-infektion med påvisning af interferonfølsomhed (historisk defineret som fald i hcv-RNA viral-load ≥ 2 log10 i uge 12 eller ikke- detekterbart hcv-RNA ved afslutning af tidligere behandling med efterfølgende detekterbart hcv-RNA i plasma), og hvor tidligere behandling med peginterferon alfa og ribavirin havde svigtet.
RESPOND-2 (P05101) was a randomized, parallel-group, double-blinded study comparing two therapeutic regimens of Victrelis 800 mg orally three times daily in combination with PR [peginterferon alfa-2b 1.5 µg/kg/week subcutaneously and weight-based ribavirin (600  1,400 mg BID) orally divided twice daily] compared to PR alone in adult subjects with chronic hepatitis C HCV genotype 1 infection with demonstrated interferon responsiveness (as defined historically by a decrease in HCV-RNA viral load ≥ 2 log10 by Week 12 or undetectable HCV-RNA at end of prior treatment with a subsequent detectable HCV-RNA in plasma) and who failed prior treatment with peginterferon alfa and ribavirin.
Respondent-analyse (post-hoc) (e) n(%)
Responder analyses (post-hoc) (e) n(%)
Respondenter (responsrate)2
Responders (Response rate2)
Respondenter, % af patienterne
Excipients
Respondenter, % af patienterne
N = number of patients
Respondenter, % af patienterne
Responders, % of patients
Respondenter, n (%)
Responders, n (%)
Respondentrate
Responder rate
Respondentrate (sekundært endepunkt)
Responder rate (secondary endpoint)
Respondentrater
Responder rates
Responder-analyse
Responder Analysis
Respondere (%)
329 333
Respondere (N, %)
Responders (N, %)
respondere1
responders1
Responderende patienter
Responders
Respons
Responded
Respons
Response to
Respons ( %)
Respons e (%)
Respons (%)
Response (%)
Respons (95 % CI)
Response (95% CI)
respons (CHR)
response (CHR)
Respons (hiv-1- RNA < 50 kopier/ml ved uge 24)
Response (HIV-1 RNA < 50 copies/ml at week 24)
Respons (komplet respons/partielt respons) Stabil sygdom
Responder (Complete Response/Partial Response) Stable Disease
Respons (konfirmeret
Response (confirmed
Respons (n: kvalificeret til respons)
Overall response rate
respons *
response
Respons bestemt på parametre for global klinisk funktion
Response in Clinical Global Functioning Measures
Respons blev defineret som et lavt indhold af viralt dna i blodet sammen med enten en tilbagevenden til normale mængder af leverenzymet alanin- aminotransferase [ALT], eller at markøren for hepatitis B-virus forsvinder fra blodet.
A response was defined as low levels of viral DNA in the blood, together with either the levels of a liver enzyme called alanine aminotransferase (ALT) returning to normal or the marker for the hepatitis B virus disappearing from the blood.
Respons blev observeret hos 13/18 (72 %, 95 % sikkerhedsintervaller: 47, 90) af DepoCyte patienterne versus 3/17 (18 % patienter, 95 % sikkerhedsintervaller: 4, 43) i den uindkapslede arm.
Responses were observed in 13/18 (72%, 95% confidence intervals: 47, 90) of DepoCyte patients versus 3/17 (18% patients, 95% confidence intervals: 4, 43) in the unencapsulated cytarabine arm.
respons CR+PR (dage)
CR+PR (days)
Respons defineret som fald fra baseline i samlet PANSS-score ≥ 20 %
Response defined as decrease from baseline in PANSS Total Score ≥ 20
Respons defineret som fald i samlet PANSS-score ≥ 20 % i forhold til baseline
Response defined as decrease from baseline in PANSS Total Score ≥ 20
Respons efter booster
Booster response
Respons efter tillæg af emtricitabin er ekskluderet (i alt 17 forsøgspersoner i begge studier). b Forbedring af Knodells nekroinflammatoriske score på mindst 2 point uden forværring af Knodells fibrosescore.
Response after addition of emtricitabine is excluded (total of 17 subjects across both studies). b Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis score.
Respons efter underkategori
Response by subcategory
RESPONS FRA PATIENTER MED ANKYLOSERENDE SPONDYLITIS I ET PLACEBO- KONTROLLERET STUDIE
Responses of Patients with Ankylosing Spondylitis in a Placebo-controlled Trial
RESPONS FRA PATIENTER MED ANKYLOSERENDE SPONDYLITIS I ET PLACEBOKONTROLLERET STUDIE
Responses of Patients with Ankylosing Spondylitis in a Placebo-controlled Trial
Respons hos patienter med ankyloserende spondylitis i et placebo-kontrolleret studie
Responses of patients with ankylosing spondylitis in a placebo-controlled trial
RESPONS HOS PATIENTER MED PSORIASISARTRIT I PLACEBO-KONTROLLEREDE FORSØG
Responses of Patients with Psoriatic Arthritis in a Placebo- Controlled Trial
Respons hos patienter med psoriasisartrit i placebo-kontrollerede studier
Responses of patients with psoriatic arthritis in a placebo-controlled trial
RESPONS HOS PATIENTER MED PSORIASISARTRIT I PLACEBOKONTROLLEREDE FORSØG
Responses of Patients with Psoriatic Arthritis in a Placebo- Controlled Trial
Respons hyppigheder (NC = Fa)
Responder rates (NC = Fa)
Respons kan ikke evalueres (not evaluable, NE)
Response Not Evaluable (NE)
Respons over 12 uger i gruppen med utilstrækkeligt respons på laksantia
Response over 12 weeks in the LIR group
Respons på
Response to
Respons på apremilast var hurtigt, med signifikant større forbedringer i tegn og symptomer på psoriasis, herunder PASI, hudbesvær/smerter og pruritus, sammenlignet med placebo efter uge 2.
Response to apremilast was rapid, with significantly greater improvements in the signs and symptoms of psoriasis, including PASI, skin discomfort/pain and pruritus, compared to placebo by Week 2.
Respons på behandling er bestemt ved et fald i blodfenylalanin efter Kuvan behandling.
Response to treatment is determined by a decrease in blood phenylalanine following treatment with Kuvan.
Respons på behandlingen disse 2 forsøg er vist i Tabel 13.
The response to treatment in both of these trials is presented in Table 13.
Respons på behandlingen disse to undersøgelser er vist i Tabel 13.
The response to treatment in both of these trials is presented in Table 13.
Respons på behandlingen i disse 2 fosøg er vist i Tabel 13.
The response to treatment in both of these trials is presented in Table 13.
Respons på effektmål i placebo-kontrolleret Aksial SpA-Studie
Efficacy Response in Placebo-Controlled Axial SpA Study
Respons på IMBRUVICA er vist i tabel 8.
Responses to IMBRUVICA are shown in Table 8.
Respons på tidligere HCV- behandling
Response to prior HCV treatment
Respons rate ialt (CR+PR) (%) p-værdi
Overall response rate (CR+PR) (%)
Respons rate på  60% bedring i mEASI (Primær parameter)§§
Response rate of  60% improvement in mEASI (Primary Endpoint)§§
Respons raten i 0,1% tacrolimus gruppen (71,6%) var signifikant højere end den i gruppen med lokal kortikosteroid behandling (50,8%,
The response rate in the 0.1% tacrolimus group (71.6%) was significantly higher than that in the topical corticosteroid based treatment group (50.8%; p<0.001; Table 1).
Respons Uge 24 Uge 48
Response Week 24 Week 48
Respons var defineret som en forbedring på mindst 3 point på mTDS-skalaen.
Responder rate was defined as at least a 3-point improvement in modified Teacher’s Drooling Scale (mTDS).